IMDX

Insight Molecular Diagnostics Stock Analysis

AI Rating

Low
  • Quality0/10
  • Growth↓ 3/10
  • Value↓ 0/10
Insight Molecular Diagnostics sales and earnings growth
IMDX Growth
Neutral
  • Revenue Y/Y↑ 115.58%
  • EPS Y/Y↑ 64.59%
  • FCF Y/Y↓ -19.66%
Insight Molecular Diagnostics gross and profit margin trends
IMDX Profitability
Neutral
  • Gross margin ↑ 56.70%
  • EPS margin↓ -1238.50%
  • ROIC 5Y↓ -979.88%
Insight Molecular Diagnostics net debt vs free cash flow
IMDX Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↓ -459.7

Insight Molecular Diagnostics stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

↗ More Diagnostics & Research stocks